CIK 0001672619 · Non-accelerated filer
Enliven Therapeutics, Inc.
Sign in to watch- Ticker
- ELVN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 811523849
- Phone
- 650-547-5814
- Business address
- 205 PARK ROAD, BURLINGAME, CA, 94010
- Former names
- IMARA Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $2,230,845
- in 7 filings, $1.6M under 10b5-1 plans
Net −$2,230,845. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 37 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-09-17 | Collins Helen Louise CHIEF MEDICAL OFFICER | Sale 10b5-1 | −2,916 | $50.03 | $146K | 27,084 |
| 2026-09-17 | Collins Helen Louise CHIEF MEDICAL OFFICER | Sale 10b5-1 | −1,844 | $50.71 | $94K | 25,240 |
| 2026-09-17 | Collins Helen Louise CHIEF MEDICAL OFFICER | Sale 10b5-1 | −240 | $51.48 | $12K | 25,000 |
| 2026-09-17 | Collins Helen Louise CHIEF MEDICAL OFFICER | Option exercise · Stock Option (right to buy) 10b5-1 | −5,000 | 106,268 | ||
| 2026-08-17 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −4,630 | $58.35 | $270K | 41,424 |
| 2026-08-17 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −1,388 | $59.35 | $82K | 40,036 |
| 2026-08-17 | Collins Helen Louise CHIEF MEDICAL OFFICER | Option exercise 10b5-1 | +5,000 | $2.48 | $12K | 30,000 |
| 2026-08-17 | Collins Helen Louise CHIEF MEDICAL OFFICER | Sale 10b5-1 | −3,900 | $58.37 | $228K | 26,100 |
| 2026-08-17 | Collins Helen Louise CHIEF MEDICAL OFFICER | Sale 10b5-1 | −1,100 | $59.35 | $65K | 25,000 |
| 2026-08-17 | Collins Helen Louise CHIEF MEDICAL OFFICER | Option exercise · Stock Option (right to buy) 10b5-1 | −5,000 | 111,268 | ||
| 2026-08-04 | Derynck Mika K Director | Option exercise 10b5-1 | +87,373 | $2.48 | $217K | 87,373 |
| 2026-08-04 | Derynck Mika K Director | Option exercise 10b5-1 | +27,567 | $25.28 | $697K | 114,940 |
| 2026-08-04 | Derynck Mika K Director | Option exercise 10b5-1 | +23,364 | $14.85 | $347K | 138,304 |
| 2026-08-04 | Derynck Mika K Director | Option exercise 10b5-1 | +20,491 | $22.47 | $460K | 158,795 |
| 2026-08-04 | Derynck Mika K Director | Sale 10b5-1 | −158,795 | $60.21 | $9.6M | 0 |
| 2026-08-04 | Derynck Mika K Director | Option exercise · Stock Option (right to buy) 10b5-1 | −87,373 | 0 | ||
| 2026-08-04 | Derynck Mika K Director | Option exercise · Stock Option (right to buy) 10b5-1 | −27,567 | 0 | ||
| 2026-08-04 | Derynck Mika K Director | Option exercise · Stock Option (right to buy) 10b5-1 | −23,364 | 0 | ||
| 2026-08-04 | Derynck Mika K Director | Option exercise · Stock Option (right to buy) 10b5-1 | −20,491 | 0 | ||
| 2026-07-17 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Option exercise 10b5-1 | +1,072 | $2.48 | $3K | 52,072 |
Page 2 of 37 · 724 trades